SOURCES: 

William Schaffner, MD, professor of preventive drugs and infectious illness specialist, Vanderbilt College Clinical Middle, Nashville; clinical director, Nationwide Basis for Infectious Illnesses.  

Ann Falsey, MD, professor of drugs and breathing viruses researcher, College of Rochester Faculty of Drugs, Rochester, NY.

Aaron Glatt, MD, chair, Division of Drugs; leader of infectious illnesses and health facility epidemiologist, Mount Sinai South Nassau; professor of drugs, Icahn Faculty of Drugs at Mount Sinai, Oceanside, NY.

Leonard Friedland, MD, vp and director, medical affairs and public well being, vaccines, GSK.

Pfizer spokesperson.

FDA: “FDA approves first breathing syncytial virus (RSV) vaccine,” “FDA Roundup June 2.”

Global Well being Group: “Breathing Syncytial Virus (RSV) illness.”

CDC: “RSV Surveillance & Analysis,” “RSV Transmission,” “RSV Signs and Care.”

GSK: “US FDA approves GSK’s Arexvy, the arena’s first breathing syncytial virus (RSV) vaccine for older adults.”

Pfizer: “U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Breathing Syncytial Virus (RSV) in Older Adults.” 

The New England Magazine of Drugs: “Efficacy and Protection of a bivalent RSV Prefusion F Vaccine in Older Adults,”“Bivalent Prefusion F Vaccine in Being pregnant to Save you RSV Sickness in Babies,”“Breathing Syncytial Virus Prefusion F Protein Vaccine in Older Adults.”

AstraZeneca: “Nirsevimab unanimously really useful through FDA Advisory Committee for the prevention of RSV decrease breathing tract illness in babies.”